The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be ...

CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV ...

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid ...

The serum ratio of soluble CD200 to its receptor (sCD200/sCD200R) at diagnosis may serve as a potential biomarker for disease activity in antineutrophil cytoplasmic antibody (ANCA)-associated ...

Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals ...

Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.

The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be ...

Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid ...

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication Provided by GlobeNewswire May 15, 2025 4:00am ...